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PREFACE 
 
This dissertation is presented in manuscript format. The findings of the study are 
presented in chapter 3, as a manuscript as required by the regulations of the University of 
KwaZulu-Natal. This manuscript will be submitted for publication in the Journal of 
Pharmacy Practice. The reference list is cited according to the instructions for authors as 
required by the Journal of Pharmacy Practice. A complete reference list is included at 
the end of every chapter and according to the reference style of the University of 
KwaZulu-Natal.  
 
The dissertation consists of four chapters as follows: 
 Chapter 1: provides an introduction to the study as well as the aims, objectives 
and a brief overview of the methodology.  
 Chapter 2: provides the literature background to the study.  
 Chapter 3: consists of the results, discussion and conclusion written in a 
manuscript format.  
 Chapter 4: provides the general conclusions, recommendations, limitations and 
strengths of the study.  
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ABSTRACT 
 
Objective 
Reporting of adverse drug reactions (ADRs) in Namibian public health facilities is 
routinely done through safety yellow forms which are forwarded to the Therapeutics 
Information and Pharmacovigilance Centre (TIPC) for further assessment and possible 
interventions. This study investigated the awareness and knowledge of healthcare 
practitioners (HCPs) regarding the ADR reporting system in the country. 
 
Methods  
A cross-sectional study was conducted via a self-administered questionnaire at two state 
hospitals in Namibia; one located in the Khomas region and the other located in the 
Hardap region. The questionnaire was distributed to HCPs in current practice dealing 
directly with medication and it included a combination of open-ended, closed-ended and 
multiple-choice questions. Questionnaires were distributed in hard copy form during the 
period of 1 October 2019 up until 15 December 2019. Data was coded and transcribed 
into Microsoft® Excel® 2016 and analysed with SPSS® for IOS version 24. 
  
Results 
One-hundred and three completed questionnaires were received. Sixty-eight percent of 
the respondents were nurses, 24.3% were medical doctors and 7.8% were pharmacists. 
The majority of HCPs (73.8% and 56.3% respectively) were able to define the terms 
“adverse drug reaction” and “pharmacovigilance” correctly while only 41.7% correctly 
defined “spontaneous reporting”. The majority of HCPs (60.2%) have identified an ADR 
in practice; however only 36.9% reported this following the approved process. Only 
48.5% of HCPs were aware of the safety yellow form for ADRs and 63.1% of HCPs did 
not know where to obtain the form. Furthermore only 37.9% of HCPs knew the name of 
the drug regulatory authority in Namibia. 
 
 Conclusion  
Awareness and knowledge of ADR reporting systems by HCPs in Namibia is insufficient. 
While HCPs deem it necessary to report ADRs, reporting is unacceptably low leading to 
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serious concerns regarding continuous monitoring of drug safety. Pharmacists showed 
better awareness compared to other HCPs and can, therefore, be best utilised as focal 
points in pharmacovigilance protraction. Mass awareness programs by the TIPC and other 
stakeholders need to be established to expand pharmacovigilance among HCPs. 
 
Keywords: Adverse drug reaction, awareness/knowledge, reporting, healthcare 
professionals, pharmacovigilance and Namibia. 
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CHAPTER 1 
INTRODUCTION 
“Pharmacovigilance is concerned with two outcomes: safety and efficacy. Does a drug work 
and is it safe? It touches on almost every aspect of the drug lifecycle from pre-clinical 
development to post-market surveillance” [Monique Ellis: 2017].  
Adverse drug reaction (ADR) reporting is the cornerstone of drug safety in pharmacovigilance 
(PV) which involves the detection, evaluation and prevention of adverse drug effects [1]. 
Health professionals remain integral to the PV process to ensure that drug-related adverse 
events are appropriately identified, collected and subsequently reported to the relevant 
regulatory bodies. 
ADR reporting relies on a system in place through which health professionals can delineate 
adverse drug effects to the relevant regulatory authorities. If there is no active awareness of 
such reporting systems, the level of ADR reporting remains remarkably low [1]. Being a 
cornerstone of PV, the question thus arises as to the knowledge of healthcare professionals 
(HCPs) with regards to ADR reporting procedures. The aim of this study is therefore to 
determine the level of awareness of ADR reporting processes in some facilities in Namibia as 
well as to determine if correct procedures are being followed to pass on the information as 
required by the drug safety regulatory authorities. 
1.1 Background and rationale for this study 
In all countries, national PV systems rely heavily on spontaneous reporting by HCPs, 
manufacturers or directly by patients. Of all the sources of data for drug safety monitoring, the 
spontaneous reporting by HCPs provides the highest volume of information at the lowest 
maintenance cost, and has proven its value in the early detection of safety issues related either 
to the products themselves or to their use [2].  The success of spontaneous reporting however 
requires substantial awareness and knowledge of such available systems from the HCPs 
concerned [2].   
 The lack of awareness and knowledge among healthcare professionals regarding ADR systems 
is very well-publicized in the literature [3, 4, 5].  This results in under-reporting and ADRs not 
always identified in preventable cases, especially in developing countries [6]. This lack of 
awareness has profound effects on the public health system as ADRs, which would normally 
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be detected, continue to contribute to high morbidity and mortality rates, putting an economic 
burden on already strained healthcare systems [7]. Levels of ADR reporting are universally 
poor and more effective dissemination and implementation of available knowledge is needed 
together with better use of the systems already available in place.  
1.2 Research questions 
This study focused on the following research questions posed to HCPs: 
1.2.1 Do HCPs understand the term adverse drug reaction and have they ever encountered it 
in practice? 
1.2.2 Is it necessary to report an ADR and do HCPs believe it is their professional 
obligation to do so? 
1.2.3 What are HCPs’ awareness of ADR reporting systems in Namibia? 
1.2.4 Are HCPs aware of the existence of a Therapeutics Information and Pharmacovigilance 
centre (TIPC) at the Namibia Medicines Regulatory Council (NMRC) under the 
ministry of health and social services which handles ADR reporting? 
1.2.5 What are HCPs’ knowledge of the safety yellow forms for ADR reporting which are 
available at the facilities? 
 
1.3 Aims and objectives of the study 
The aim of this study was to assess awareness and knowledge of doctors, pharmacists and 
nurses (collectively referred to as healthcare professionals) in Namibia regarding ADR 
reporting procedures. To achieve this, the following objectives were outlined: 
1.3.1 To determine if HCPs understand what ADRs are. 
1.3.2 To determine if HCPs can detect ADRs. 
1.3.3 To establish if HCPs deem it necessary to report ADRs as part of their professional 
responsibilities. 
1.3.4 To establish if HCPs have the knowledge of processes that occur after submission of 
an ADR form. 
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1.4 Significance of the study 
This study gives an indication of the extent to which HCPs in Namibia are aware of ADR 
reporting systems in the country with the aim to detect and minimize the occurrence of ADRs. 
Their knowledge of reporting systems was also determined to devise various educational 
interventions designed to influence reporting behaviour.  
As per requirement by the Ministry of Health and Social Services in Namibia (MOHSS) as 
stated in the permission letter, the results of this study will be submitted to the Ministry upon 
completion. In particular, the Therapeutics Information and Pharmacovigilance Centre (TIPC) 
which falls under the NMRC will be able to use the results of this study to design robust 
intervention methods and awareness campaigns required to increase or improve ADR reporting 
awareness among nurses, doctors and pharmacists. It is envisaged that when HCPs are better 
equipped to detect and report ADRs through sensitization from the TIPC, there will be an 
increase in drug safety and positive patient outcomes. Accordingly, the TIPC will also be able 
to utilize the outcomes of this study to strengthen national pharmacovigilance systems as a 
mandate to the Namibian government in ensuring the national provision of medicines which 
are of good quality and are safe and effective. 
Adverse drug reactions (ADRs) are a major cause of patient-related morbidity and mortality 
and awareness of HCPs to ADR reporting systems in Namibia will play a huge role in effective 
and safe clinical practice [8]. 
1.5 Research methodology 
1.5.1 Study design and setting. 
A cross-sectional quantitative survey, with the aid of a self-administered questionnaire, was 
conducted at two state hospitals located in the Khomas and Hardap regions in Namibia. The 
Khomas-based hospital is a referral-only, tertiary level, national institution which deals with 
larger patient volumes, while the Hardap-based facility is a district hospital that provides care 
at secondary level. The study targeted specific HCPs i.e. nurses, doctors and pharmacists. The 
survey was conducted from the 1st of October 2019 to the 15th of December 2019. 
HCPs not included in this study were those who did not deal directly with medication and those 
who were not in practice at either of the two study sites. Awareness and knowledge of ADR 
reporting systems outside Namibia were also not considered. 
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1.5.2   Questionnaire design 
All questionnaires were administered in English and consisted of 22 questions in total. The first 
four questions in section 1 of the survey assessed demographics such as type of profession, 
gender, educational qualifications attained and the number of years in practice. Section 2 
included three open-ended questions that assessed knowledge of the terms “adverse drug 
reaction”, “pharmacovigilance” and “spontaneous reporting”. Section 3 of the questionnaire 
had fifteen questions and included a mix of both close-ended and multiple-choice questions 
designed to assess knowledge on specific ADR reporting systems in the country such as correct 
knowledge of the drug regulatory authority (question 20) and the ADR reporting tool (question 
18 and 19). Section 3 also assessed knowledge on ADR causality (question 8), type of ADRs 
to be reported and for which products (question 9 and 10), the seriousness of ADRs (question 
12), ADR identification, reporting and professional responsibility (question 11, 13, 14, 15 and 
22), training on ADR reporting systems (question 16 and 17) and the actions that the regulatory 
authority can take after ADR form submission (question 21). 
For the open-ended questions investigating knowledge of terms, the correct definition was 
determined by looking for key relevant wording in the responses and not necessarily the exact 
scientific definition. Some of the multiple-choice questions had more than one correct option 
to choose from and this was clearly indicated to the participants. 
To improve the survey, the questionnaire was tested before use to determine if it was clear, 
relevant/appropriate to the study purpose and not open to more than one interpretation to 
eliminate any threat to face and content validity. To address this issue, a group of 10 HCPs (3 
medical doctors, 5 nurses and 2 pharmacists) were piloted. All the HCPs involved in the 
questionnaire evaluation study were able to complete the questionnaire without any difficulty 
and their positive feedback to the simplicity and clarity of the questions was noted. These 
responses were not included in the data analysis. 
1.5.3   Data Analysis 
The collected data was coded, entered into Microsoft® Excel® 2016 and subsequently analysed 
using SPSS for IOS version 24. The data compiled was then analysed using descriptive 
statistics. Correlational techniques were further carried out to analyse the possible relationship 
between certain variables. ANOVA analysis was done to investigate if there were significant 
differences between the different professions in the way that they answered certain questions. 
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1.5.4 Ethical approval 
Full ethical approval was obtained from the University of Kwazulu-Natal’s Biomedical 
Research Ethics Review Committee (BREC) - reference number BE489/19. In line with BREC 
recommendations, distributed questionnaires were accompanied by a letter of invitation 
outlining the purpose of the study to the potential participants, as well as an informed consent 
document (see Annexure 5) which was signed by the participants. 
1.5.5 Permission from Ministry of Health and Social services Namibia.  
This study was given gatekeeper approval by the Ministry of Health Facilities. The research 
proposal was evaluated by the research department and found to have merit (REF number 
17/3/3 GD). 
1.6 Chapter 1 summary 
This chapter summarizes the study’s rationale and significance, research questions, aims, 
objectives and a brief outline of the research methodology. 
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CHAPTER TWO 
LITERATURE REVIEW 
2.1 Introduction 
The Namibia Medicines and Related Substances Control Act, (MRSCA) Act. No. 13 of 2003 
requires every registration holder and healthcare professional to inform the Namibia Medicines 
Regulatory Council of any ADR which occurs during the use of any medicine [1]. Established 
in 2006 and officially launched in May 2008, the Therapeutic Information and 
Pharmacovigilance Centre (TIPC) was set up under the Ministry of Health and Social Services 
to promote the safe and rational use of medicines in Namibia. This has seen Namibia being 
fully admitted as the 90th member country and collaborating centre of the World Health 
Organisation (WHO) International Drug Monitoring program [1]. 
The specific objectives of the TIPC are to provide both proactive and query response 
information to HCPs and the general public in Namibia and to become a reference unit on 
pharmacovigilance by collecting and monitoring adverse reactions [1]. 
In developing nations such as Namibia, the scourge of infectious diseases such as malaria, 
tuberculosis and HIV has seen a fast track in the registration of essential medicines [1]. With 
prolonged use of these medications however, ADRs are more likely to be observed. The TIPC 
relies on information from HCPs on the ground by way of spontaneous reporting to monitor 
such adverse reactions. Spontaneous reporting of ADRs in Namibia is done via the completion 
of a “safety yellow form” (See Annexure 3) for onward submission to the NMRC. 
Safety yellow forms are available in all public health facilities. HCPs can send the forms either 
directly to the NMRC, or the pharmacists in the hospitals who then forward the forms to the 
NMRC, which harbours the TIPC [1]. 
The information collected by the TIPC is entered into a database which is occasionally 
reviewed. This leads to one of many possible actions which can include labelling changes on 
the product, communication of alerts to HCPs about the adverse reaction and in some cases a 
complete withdrawal of the product from the market [1]. 
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2.2 Previous recommendations on PV in Namibia 
Adenuga (2018) highlights how ADRs are hugely under-reported by HCPs in Namibia [2]. The 
TIPC, however, as established by the MOHSS in Namibia, has not been fully utilised to its 
maximum potential since inception. About half of all nurses, doctors and pharmacists seem not 
to know how to report ADRs to the TIPC, let alone being aware of any ADR reporting systems 
in place [2]. This has led to recommendations which include the need for cross-sectional studies 
to be conducted in both the public and private sectors to investigate the awareness and 
knowledge of HCPs to ADR reporting systems in the country [2]. A further recommendation 
is that training on PV should also not be solely confined to the workplace, but also be 
incorporated into the academic curriculum to have a better chance of strengthening PV systems 
throughout the whole country [2]. 
 
2.3 PV monitoring and background. 
The WHO programme for International Drug Monitoring first came into effect in the 1960s 
following the Thalidomide disaster [3]. Since then PV monitoring has grown exponentially, 
but mainly in developed countries, owing to reporting from healthcare professionals and 
pharmaceutical companies. In developed countries, ADR reporting systems and programs 
remain above par since early inception. For instance in the UK, 17000 ADR reports are 
recorded per annum according to the yellow card scheme [4]. In the US, active PV systems 
such as MedWatch and Sentinel Events Reporting Programs actively engage all HCPs [6]. The 
Netherlands has a large scale spontaneous ADR reporting program which was launched as 
early as 1963 [5]. A lot of resources are allocated into ensuring that HCPs are aware of these 
different ADR reporting systems [6]. Toolkits, such as SCOPE, have been widely introduced 
in European Union member states to increase awareness levels of national spontaneous ADR 
reporting systems [6]. Despite these major headways in PV advancement, adverse drug event 
reporting awareness in developed countries is still insufficient [7]. Studies that evaluated the 
knowledge and attitudes of US pharmacists regarding ADRs show that, despite favourable 
attitudes toward reporting, many pharmacists have never reported an adverse event or admit to 
having inadequate knowledge regarding reporting mechanisms [7]. This does not apply to the 
US alone, many other studies in several European countries have revealed a lack of pharmacist 
awareness with ADR reporting [5, 8, 10]. Pharmacists are regarded as the focal point of PV 
monitoring to ensure drug safety; however, if awareness to ADR reporting is scant among 
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pharmacists themselves, then this is more likely to be the same scenario for other HCPs such 
as doctors and nurses who are equally fundamental to PV propagation. A cross-sectional 
observational study by Gupta (2017) in India noted that 88% of doctors did not know the 
authority and the procedure for ADR reporting [16]. Shamim (2016) in southern India 
concluded that nurses had only moderate awareness and practice was very poor [9]. 
In low- and middle-income countries the situation remains perturbing: PV awareness, in 
general, remains a major challenge amidst strained resources and diversion of funds towards 
higher priority areas [7]. This places the majority of people at risk; developing countries have 
of late been getting an influx of new drugs either through direct importation or donations, 
unfortunately, some of these drugs may be of poor quality [15]. The drugs imported from 
developed countries may even have a different safety profile in some developing countries due 
to genetic and social differences [15]. In light of this, there is a dire need to strengthen ADR 
reporting systems in developing countries to minimize risks due to ADRs. All HCPs need to 
be omniscient to these systems as ADRs are preventable most of the time and awareness of 
early detection can be the difference between life and death. In the year 2011 in Pakistan, over 
100 patients lost their lives because of counterfeit antihypertensive medication at a prominent 
cardiology hospital [9]. Needless to say, if HCPs at the time were aware of any PV system in 
place, this calamity would have been avoided on a larger scale. 
 
2.4 Awareness and under-reporting. 
Literature lists many barriers to ADR reporting and lack of awareness remains increasingly 
recurrent [9, 10, 11]. In fact lack of awareness is closely tied to under-reporting of ADRs and 
is very common [9]. It has been estimated that only 6-10% of all ADRs are reported [16]. In a 
cross-sectional observational study conducted in India, the main reason for the under-reporting 
of ADRs among resident doctors was due to a lack of awareness of the reporting procedure 
[16].  
In another study conducted among nurses in both private and public hospitals in Dar Es Salaam, 
Tanzania, the majority (61.9%) of the participants strongly agreed that lack of knowledge about 
ADR reporting techniques contributed to fewer ADRs being officially registered to the 
regulatory authority [17]. 
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2.5 Lack of awareness and knowledge of ADR reporting systems. 
Lack of awareness of ADR reporting systems among HCPs has been highlighted in many 
research studies as the major impediment to successful PV [8, 9, 10, 16, 17]. In a 2017 study 
done in South Africa, a baseline analysis was conducted to investigate knowledge, attitudes 
and perceptions on adverse drug reaction reporting in a public sector hospital [10].  In this 
study, data was collected using self-administered questionnaires targeting all medical 
practitioners, nurses, pharmacists and pharmacist assistants at a public sector hospital.  The 
vast majority indicated ADR reporting is necessary (96.2%) and that it is their professional 
obligation (89.4%), but only 18.9% were aware of an existing PV reporting system in the 
hospital, 15.2% had an ADR form available and 18.9% knew to whom the form should be 
submitted. Additionally, the vast majority had never reported an ADR. Owing to this dismal 
lack of awareness, the researchers had to recommend extensive training on ADR reporting.  
In another study, awareness about ADR reporting among doctors, pharmacists and nurses was 
measured to determine reasons for ADR under-reporting in Pakistan public hospitals [9].  The 
findings depicted only 43.4% of HCPs knew the term pharmacovigilance and ADR reporting. 
Only 31.7% of respondents knew that there is an ADR reporting form at the website of the 
Drug Regulatory Authority of Pakistan (DRAP). Furthermore only 14.3% of HCP respondents 
knew that there is any ADR reporting organization in Pakistan. About 77.3% of respondents 
understood the importance of reporting ADRs although only 38.9% confessed the presence of 
ADR reporting systems in their respective healthcare system. Considering the importance of 
ADR reporting, the study showed inadequate knowledge among HCPs about adverse drug 
reactions and reporting.  
A cross-sectional study was also done at selected public hospitals in northeast Ethiopia to 
investigate knowledge, attitude, and practice of 114 HCPs about ADRs [18]. One-hundred 
(87.7%) respondents knew that all drugs available in the market are not safe but only 23 
(20.2%) respondents knew the term pharmacovigilance and understood its function. Likewise, 
24 (21.1%) and 26 (22.8%) respondents knew about the availability of a national reporting 
system and ADR reporting form in Ethiopia, respectively. Thirty-five (30.7%) respondents 
knew the responsible body that monitors ADRs in Ethiopia. Moreover, a significant proportion 
of the respondents, 93 (81.6%) and 52 (45.6%) replied that ADRs should be reported only when 
they are serious and life-threatening and severe and cause disability, respectively. The study 
also found that only 24 (29.82%) respondents encountered at least one patient with ADR in the 
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past 12 months of their clinical practice, out of which 24 (70.59%) and 17 (50%) respondents 
recorded and reported ADRs, respectively. The study identified that HCPs had inadequate 
knowledge on ADR reporting and had poor ADR reporting practices which contributed to 
under-reporting in hospitals despite the majority having a favourable attitude towards ADR 
reporting. Taking into account the findings of the study, it was concluded that creating 
awareness and improving the knowledge of all HCPs through regular sensitization programs, 
trainings, and timely feedback is a very crucial strategy to enhance spontaneous ADR reporting 
in health facilities to the concerned body, which ultimately impacts the provision of quality 
patient care [18]. 
To emphasize the importance of awareness and sensitization, a Structured Pharmacovigilance 
and Training Initiative (SPHAR-TI) model based on the WHO accredited Structured 
Operational Research and Training Initiative (SOR-IT) model was designed to improve the 
reporting of ADRs in public health programs treating HIV, TB and Malaria in Nigeria [11]. 
The major finding of this evaluation was the significant gain in awareness and knowledge 
observed among the participants generally. Participants also developed the capacity to detect 
and accurately report ADRs, including serious ADRs such as Steven Johnson Syndrome and 
bilateral gynaecomastia. 
This summarised literature review affirms the need to increase awareness of ADR reporting 
systems among healthcare professionals to improve public health and safety in relation to the 
use of medicines. Even in developed European countries with robust reporting and response 
systems, awareness still remains a major issue and there will always be a need to continually 
sensitize HCPs to the need for ADR reporting [7]. Priyadharsini (2017) appropriately sums it 
up in his study that HCPs were aware of the concept of ADRs but the majority did not know 
how and where to report. Thus, the creation of awareness amongst HCPs is the most important 
determinant influencing spontaneous reporting of ADRs. Safe to say, there will always be a 
need to address this awareness as long as ADRs are still one of the leading causes of morbidity 
and mortality in healthcare [12]. In Canada, ADRs cause 10000 to 22000 deaths and cost the 
Canadian healthcare system over $13 billion per year [12]. In the United States, 26500 children 
die from ADRs each year [12].  Unlike the pattern in high-income countries, the drugs 
implicated in ADR-related deaths in developing countries are mostly drugs used in the 
treatment of HIV and tuberculosis, reflecting the high burden of these diseases [15]. These 
ADRs are implicated in 2.5–18% of deaths of hospitalized patients and fatal ADRs are 
frequently preventable [13]. 
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2.6 Other challenges to PV implementation. 
Unfortunately, a few challenges affect the extent to which HCPs are aware of ADR reporting 
systems in their respective practices. Belete (2016) outlines how the unavailability of ADR 
reporting forms played a huge role in significantly discouraging healthcare professionals from 
detecting and reporting ADRs in Boru Meda Hospital, North East Ethiopia [14]. Awareness 
proves largely futile if the safety forms which are needed for reporting are not made readily 
accessible and this impacts poorly on achieving positive patient outcomes. 
Regulatory authorities also have a mandate to ensure the establishment and maintenance of 
strong PV systems which are clear and concise enough to be followed by HCPs [14]. Healthcare 
professionals will not conform to any ADR reporting system which is ambiguous. 
As much as HCPs are aware of ADR reporting systems available to them, other factors can 
also impede reporting such as difficulty in deciding if it is an adverse drug reaction or not, lack 
of motivation due to non-remuneration and a lack of time due to busy working hours or patient 
overload [9,10,11]. These issues are equally pertinent and also require equal priority. 
 
2.7 Chapter summary 
This chapter summarizes the literature review pertaining to the well-publicised lack of 
awareness of ADR reporting systems. It also highlights the background of PV in Namibia and 
the role of the TIPC in ADR reporting.  
 
. 
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ABSTRACT 
Objective 
Reporting of adverse drug reactions (ADRs) in Namibian public health facilities is routinely 
done through safety yellow forms which are forwarded to the TIPC for further assessment and 
possible interventions. This study investigated the awareness and knowledge of healthcare 
practitioners (HCPs) regarding the ADR reporting system in the country. 
 
Methods 
A cross-sectional study was conducted via a self-administered questionnaire at two state 
hospitals in Namibia; one located in the Khomas region and another one located in the Hardap 
region. The questionnaire was distributed to HCPs in current practice dealing directly with 
medication and it included a combination of open-ended, closed-ended and multiple-choice 
questions. Questionnaires were distributed in hard copy form during the period of 1 October 
2019 up until 15 December 2019. Data was coded and transcribed into Microsoft® Excel® 
2016 and analysed with SPSS® for IOS version 24. 
 
Results 
One-hundred and three completed questionnaires were received. Sixty-eight percent of the 
respondents were nurses, 24.3% were medical doctors and 7.8% were pharmacists. The 
majority of HCPs (73.8% and 56.3% respectively) were able to define the terms “adverse drug 
reaction” and “pharmacovigilance” correctly while only 41.7% correctly defined “spontaneous 
reporting”. The majority of HCPs (60.2%) have identified an ADR in practice; however only 
36.9% reported this following the approved process. Only 48.5% of HCPs were aware of the 
safety yellow form for ADRs and 63.1% of HCPs did not know where to obtain the form. 
Furthermore only 37.9% of HCPs knew the name of the drug regulatory authority in Namibia. 
 
 Conclusion 
Awareness and knowledge of ADR reporting systems by HCPs in Namibia is insufficient. 
While HCPs deem it necessary to report ADRs, reporting is unacceptably low leading to serious 
concerns regarding continuous monitoring of drug safety. Pharmacists showed better 
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awareness compared to other HCPs and can, therefore, be best utilised as focal points in 
pharmacovigilance protraction. Mass awareness programs by the TIPC and other stakeholders 
need to be established to expand pharmacovigilance among HCPs. 
 
Keywords: Adverse drug reaction, awareness/knowledge, reporting, healthcare 
professionals, pharmacovigilance and Namibia. 
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Background and introduction 
Namibia has an approximate population of 2.5 million and is classified as an upper-middle 
income developing country [1]. A high disease burden however exists and national public 
health disease control programmes, such as HIV/AIDS, malaria and tuberculosis programmes, 
have placed a large strain on the country’s resources [1].These programmes have led to the 
extensive use of essential medicines and with this, the need for adequate safety monitoring. 
Adverse drug reactions (ADRs) that are not properly identified, reported and managed can 
cause harm and undermine the public’s confidence in the health system [2]. The national 
guidelines for medicine safety surveillance underline spontaneous reporting by healthcare 
professionals (HCPs) to be effective enough for early detection of unknown problems and thus 
appropriate for the Namibian setting [3]. 
The Therapeutics Information and Pharmacovigilance Centre (TIPC) was established in 2006 
with the purpose of providing therapeutics information, monitoring safety and ensuring rational 
use of medicines that are already on the Namibian market [3]. The safety yellow form, a 
simplified ADR reporting form that is made available at public health facilities in Namibia, is 
used to report any suspected ADRs for all conventional, biological, and complementary 
medicines, nutritional and dietary supplements and medical devices [3]. Completed safety 
yellow forms are submitted to the TIPC via fax or email where all case reports are analysed, 
summarised and sent to the clinical committee of the Namibia Medicines Regulatory Council 
(NMRC). After further exploration, the committee can recommend regulatory action which 
may include, but are not limited to, complete withdrawal of the product or sending out alerts 
to the prescribers, manufacturers and the consumers about the possible adverse reaction [3]. 
A well-documented challenge to the implementation of ADR reporting among HCPs is limited 
awareness and knowledge of existing reporting systems [4]. In a 2019 study, knowledge, 
attitudes and practices of HCPs towards ADR reporting in primary healthcare facilities in South 
Africa was investigated among 200 respondents [5]. Although an appropriate attitude towards 
ADR reporting existed, the actual frequency of ADR reporting was low (16.0%). Nearly two-
thirds (60.5%) of respondents did not know how to report, where to report, or when to report 
an ADR. When results were combined, the overall mean score in terms of positive or preferred 
practices for ADR reporting was 24.6% with pharmacists having the highest scores. The study 
highlighted a void in ADR reporting awareness and knowledge which is widely prevalent in 
developing countries with a high disease burden like Namibia [1, 5]. 
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The aim of this study was, therefore, to investigate the awareness and knowledge of HCPs in 
Namibia on ADR reporting systems in the country. Awareness and knowledge of these systems 
by HCPs forms the essence of medicine safety. Other factors having an influence on awareness 
and knowledge of ADR reporting systems in the country were also investigated among HCPs.  
These included knowledge on estimating the strength of a relationship between drug(s) 
exposure and the occurrence of ADRs known as causality assessment [3]. In line with the 
objectives of this study, knowledge on causality assessment will determine if HCPs can detect 
ADRs or not. Complimentary knowledge among HCPs on ADR severity, seriousness of ADRs 
and ADR reporting of certain products was also investigated as these have a cumulative effect 
on the intent of the study. 
Methods 
Study sample 
The cross-sectional study was carried out with the use of a self-administered questionnaire 
which was completed by doctors, pharmacists and nurses at 2 state hospitals. The hospital 
situated in the Khomas region is the main hospital hub of the country and also deals with 
external referrals from smaller towns. In terms of staffing, it has approximately 30 doctors, 7 
pharmacists and about 200 nurses. The state hospital in the Hardap region, which is the southern 
part of the country, handles smaller patient volumes. Only 2 pharmacists, 5 doctors and 29 
nurses are stationed there. 
One-hundred and twenty-three self-administered questionnaires were distributed between the 
two facilities as hard copies. The inclusion criteria consisted of HCPs (doctors, pharmacists 
and nurses) in full-time permanent employment at the two state hospitals dealing directly with 
medication. The exclusion criteria comprised of HCPs who do not deal directly with 
medication and those not in full-time practice at the two hospitals of interest.  
Permission to conduct the study was obtained from the Ministry of Health and Social Services 
in Namibia (MOHSS) and ethical approval was acquired from the University of Kwazulu-
Natal’s Biomedical Research Ethics Review Committee (BREC); approval number BE489/19. 
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Sampling, data collection, ethical issues and analysis  
In this study, two types of purposive sampling techniques were used - total population sampling 
and random sampling.  Due to the small number of HCPs at the Hardap region hospital, all of 
the 36 HCPs were included in the study sample. All the doctors and pharmacists (n=37) at the 
Khomas central hospital were also sampled to take part in the study, but random sampling was 
initiated for nurses as the entire population of about 200 nurses was too big. A smaller sample 
size of 50 nurses were randomly selected from the medical adult ward, maternity/paediatric 
ward, oncology ward, psychiatry ward, HIV ward/clinic, and emergency ward. At a 95% 
confidence level with a margin error between 4 and 8%, 123 HCPs from a research population 
of approximately 273 was the ideal sample size. 
Questionnaires were made available at the department heads’ desks and the weekly department 
meetings. Effort was made to attend at least one of these meetings to address any questions that 
they might have had about the study. Willing participants were also asked to refer eligible 
friends or colleagues to take part in the study.  
All questionnaires were administered in English and consisted of 22 questions in total. The first 
four questions in section 1 (question 1-4) of the survey assessed demographics such as type of 
profession, gender, educational qualifications attained and the number of years in practice. 
Section 2 (question 5-7) included three open-ended questions that assessed knowledge of the 
terms “adverse drug reaction”, “pharmacovigilance” and “spontaneous reporting”. For the 
purpose of this study, the term “pharmacovigilance” was defined as the science and activities 
relating to the detection, assessment, understanding and prevention of adverse effects or any 
other drug-related problem [8]. “Adverse drug reaction” was defined as a response to a 
medicine which is noxious and unintended, and which occurs at therapeutic doses and the term 
“spontaneous reporting” was defined as a system whereby case reports of adverse drug events 
are voluntarily submitted by health professionals and pharmaceutical companies to the national 
pharmacovigilance centre [8]. For the open-ended questions investigating knowledge of terms, 
the correct definitions were determined by looking for relevant key wording in the responses 
and not necessarily the exact scientific definition. 
Section 3 (question 8-22) of the questionnaire had fifteen questions and included a mix of both 
close-ended and multiple-choice questions. Some of the multiple-choice questions had more 
than one correct option to choose from and this was clearly indicated to the participants. Under 
section 3; questions 8, 9, 10, 11 and 12 assessed knowledge on reporting, identification and 
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consequences of ADRs. Questions 13, 14 and 15 assessed if HCPs had ever identified or 
reported an ADR before in practice and if they thought it was their professional responsibility 
to do so. Training on ADR reporting was ascertained using questions 16 and 17 and the last 
five questions (18, 19, 20, 21 and 22) looked at awareness and knowledge of specific ADR 
reporting systems in Namibia. Question 21 specifically addresses the objective assessing if 
HCPs are aware of the processes which occur after submission of the ADR reporting form. 
To improve the survey, the questionnaire was piloted before use to determine if it was clear, 
relevant/appropriate to the study purpose and not open to more than one interpretation to 
eliminate any threat to face and content validity. The questionnaire was piloted amongst a 
group of 10 HCPs (3 medical doctors, 5 nurses and 2 pharmacists). All the HCPs involved in 
the pilot study were able to complete the questionnaire without any difficulty and their positive 
feedback to the simplicity and clarity of the questions was noted. 
Distributed questionnaires were accompanied by an information sheet outlining the purpose of 
the study to the potential participants, as well as an informed consent document to be signed 
by participants. Anonymity and confidentiality was strictly maintained at every stage of the 
research process without any possibility of being traced back to the participants. No personally- 
identifying information such as names, e-mail/residential/IP addresses and phone numbers 
were requested from the participants. Proper data management through coding, storage and 
security was also employed therefore no link existed between the information collected and the 
individual participants. Only the principal investigator had access to the data and no potential 
risks were associated with the study apart from possible discomfort emanating from their lack 
of awareness to adverse drug reaction reporting protocols, to counteract this, all participants 
were assured that their responses remain confidential and will never be traced back to them in 
an effort to undermine their professional status. The collected data was coded, entered into 
Microsoft® Excel® 2016 and subsequently analysed using SPSS® for IOS version 24. 
The data compiled was analysed using descriptive statistics. Correlational techniques were 
further carried out to analyse the possible relationship between certain variables and ANOVA 
analysis was also done to investigate if there were significant differences between the different 
professions in the way that they answered certain questions. 
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Results 
Overview of participant demographics 
In total, 103 questionnaires were completed (response rate of 83.7%). The HCPs referred to in 
this results section are from both hospitals collectively. The respondents comprised 59.4% of 
females and 40.6% of males. The majority of questionnaires were completed by nurses (n=70, 
68%), followed by doctors (n=25, 24.3%) and pharmacists (n=8, 7.8%). The Khomas region 
hospital accounted for the majority of participants (n=79, 76.7%) in comparison to the Hardap 
region hospital (n=24, 23.3%). The participants at the Khomas region-based hospital comprised 
53 nurses, 6 pharmacists and 20 doctors while the Hardap region-based state hospital 
constituted of 17 nurses, 2 pharmacists and 5 doctors. Educational qualifications attained for 
the respondents were as follows: diploma (n=37, 35.9%), postgraduate diploma (n=6, 5.8%), 
bachelor’s degree (n=51, 49.5%), master’s degree (n=7, 6.8%) and PhD (n=2, 1.9%).  
Most of the HCPs (n=45, 43.7%) had between 1-5 years of experience in practice, followed by 
those with more than 20 years (n=22, 21.4%), 6-10 years (n=13, 12.6%), 11-20 years (n=12, 
11.7%) and lastly HCPs who had less than a year of practice experience (n=11, 10.7%). 
Table 1 provides information on the knowledge of HCPs regarding the terminology i.e. 
“adverse drug reaction”, pharmacovigilance” and “spontaneous reporting”. Most HCPs could 
correctly define “adverse drug reaction” (73.8%) while less than half (41.7%) correctly defined 
“spontaneous reporting”. 
Table 1: Knowledge of definitions 
 Adverse drug reaction definition. 
  Incorrect Correct Total 
Profession Medical doctor 3 (12%) 22 (88%) 25 
 Pharmacist 0 (0%) 8 (100%) 8 
Nurse 24 (34.3%) 46 (65.7%) 70 
Total  27 (26.2%) 76 (73.8%) 103 
 Pharmacovigilance definition. 
  Incorrect Correct Total 
Profession Medical doctor 10 (40%) 15 (60%) 25 
 Pharmacist 0 (0%) 8 (100%) 8 
Nurse 35 (50%) 35 (50%) 70 
Total  45 (43.7%) 58 (56.3%) 103 
 Spontaneous reporting definition. 
  Incorrect Correct Total 
Profession Medical doctor 15 (60%) 10 (40%) 25 
 Pharmacist 1 (12.5%) 7 (87.5%) 8 
Nurse 44 (62.9%) 26 (37.1%) 70 
Total  60 (58.3%) 43 (41.7%) 103 
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Sixty point two percent (n=62) of HCPs indicated that they had identified an adverse reaction 
in practice. Of the 25 doctors who participated, 22 (88%) had identified an adverse reaction in 
practice whilst 75% of pharmacists (n=6) and 48.6% of nurses (n=34) had identified an adverse 
reaction before.  
Only 36.9% (n=38) of HCPs indicated that they had ever reported an adverse drug reaction. Of 
the 25 doctors who participated, 8 (32%) had reported an adverse reaction in practice whilst 
62.5% of pharmacists (n=5) and 35.7% of nurses (n=25) had reported an adverse reaction. 
However, nearly all HCPs (n=101, 98.1%) did believe that it was part of their professional 
obligation to report ADRs. 
A total of 48.5 % (n=50) of HCPs correctly identified the safety yellow form as the means to 
report ADRs in Namibia, but only 36.9% (n=38) knew where to obtain the form from. Only 
minimal 37.9% (n=39) of HCPs knew the correct regulatory authority in Namibia which is the 
TIPC that handles ADR report cases, while only 36.9% (n=38) of HCPs pointed out that they 
had been trained on ADR reporting systems. 
In terms of knowledge on causality assessment, less than half of HCPs (n=50, 48.5%) were of 
the opinion that the pharmacology of the drug can explain the suspected adverse effect and 
only 68% (n=70) thought it was necessary to know if re-exposure worsens the adverse effect 
OR withdrawal of the medicine decreases the suspected adverse event.  
HCPs were not always clear on which ADRs should be reported – 55.3% (n=57) of HCPs 
indicated that mild ADRs should be reported and just over half (51.5%, n=53) indicated that 
ADRs should be reported for herbals and traditional medicines. 
HCPs were also unsure of the role of the TIPC; although 65% (n=67) of HCPs were of the 
opinion that the regulatory authority can withdraw the product from the market only 40.8% 
(n=42) indicated that a change on the labelling of the product can occur. 
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Table 2: Summary of awareness and knowledge of healthcare practitioners on adverse 
drug reaction reporting. 
Awareness and knowledge          Response 
Identification and reporting of 
ADRs. 
Number of Respondents Percentage 
I have identified an ADR in 
practice. 
62 60.2 
I have reported an ADR before. 38 36.9 
It is necessary to report an ADR. 101 98.1 
I have received training on ADR 
reporting systems in Namibia. 
38 36.9 
Awareness of ADR reporting 
systems in Namibia. 
 
Correct knowledge of the safety 
yellow form for ADR reporting. 
50 48.5 
Indicated knowledge of where to 
obtain the safety yellow form. 
38 36.9 
Indicated awareness of the TIPC as 
the correct drug regulatory 
authority. 
39 37.9 
Knowledge of ADR causality 
assessment. 
 
It is important to know all the 
medication the patient is taking. 
93 90.3 
It is significantly important to 
know the timing between 
administration of the medicine and 
development of the suspected 
ADR. 
85 
 
82.5 
It is important to know if re-
exposure or withdrawal of the 
medicine decreases the suspected 
ADR. 
70 68 
It is important to know the 
pharmacology of the suspect drug. 
50 48.5 
ADR reporting for which 
products. 
 
Herbals and traditional medicines. 53 51.5 
Vaccines and medical devices. 94 91.3 
Biological and blood products. 82 79.6 
Type of ADRs to be reported  
Severe and life-threatening. 101 98.1 
Severe and causing disability. 90 87.4 
Mild. 57 55.3 
Knowledge of what actions the 
regulatory authority can take. 
 
Withdraw product from the 
market. 
67 65 
Change on product labelling. 42 40.8 
Sending out alerts of a possible 
adverse reaction. 
90 87.4 
Keep the suspect drug in the 
market as long as possible. 
12 11.7 
 
 
25 
 
Further analysis to determine significant relationships and differences 
 
Analysis of results found a statistically significant (p<0.05) relationship using correlational 
analysis between 1) profession and 2) educational qualifications in identifying an adverse 
reaction in practice. Similarly, training had a positive relation to 1) identifying and 2) reporting 
adverse drug reactions. Being able to identify and report an ADR was also positively associated 
to being aware of the safety yellow form.  
Multiple comparisons using ANOVA analysis were also done to investigate if there were any 
significant differences among different professions in their knowledge regarding ADRs and 
reporting thereof. Significant differences were noted in the way different HCPs responded to 
certain questions. There was a significant difference (p<0.05) between medical doctors and 
nurses in identifying an adverse reaction in practice. With regards to receiving training on  ADR 
reporting systems, significant differences were noted between medical doctors and 
pharmacists; medical doctors and nurses; pharmacists and nurses. In relation to knowledge of 
the safety form, there was a significant difference between pharmacists and medical doctors as 
well as pharmacists and nurses. Medical doctors and pharmacists along with pharmacists and 
nurses also significantly differed in knowing where to obtain the safety form. Concerning 
knowledge of the correct regulatory authority, significant differences were noted between 
medical doctors and pharmacists as well as pharmacists and nurses. 
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Discussion 
Knowledge of key terms 
Doctors, nurses and pharmacists are all collectively responsible for ADR reporting. 
Comprehension of fundamental terms such as “pharmacovigilance”, “adverse drug reaction” 
and “spontaneous reporting” underpin the ability to discharge this responsibility. The term 
“adverse drug reaction” was generally well understood yet the knowledge of the terms 
“pharmacovigilance” and “spontaneous reporting” was generally inadequate. Other research 
findings [6, 7] also correlate the results of this study were a few HCPs knew the terms 
“pharmacovigilance” and “spontaneous reporting”. The WHO maintains that spontaneous 
reporting remains the cornerstone of pharmacovigilance [8]. Knowledge of these terms is of 
the utmost importance otherwise ADR reporting remains subdued. In a previous related study 
assessing healthcare professionals’ pharmacovigilance knowledge, 35.5 % of respondents were 
not familiar with the term “pharmacovigilance” and limited pharmacovigilance knowledge was 
cited as the main reason for under-reporting of ADRs [9].  Continuous and rigorous awareness 
campaigns by the TIPC are vital to sensitize HCPs about how pharmacovigilance plays a major 
role in the safety monitoring of medicines in clinical practice and how spontaneous reporting 
remains largely integral to the implementation of this process. Pharmacists displayed 
resounding knowledge in the definition of all the terms; owing chiefly to the fact that they are 
better trained in the field of ensuring drug safety.  
Under-reporting of ADRs and proposed solutions 
The national pharmacovigilance guidelines for medicine safety surveillance, as set out by the 
MOHSS, underscore spontaneous reporting by HCPs as effective for the Namibian setting in 
the early detection of unknown problems pertaining to drug safety [3]. Despite 98.1% of HCPs 
indicating a favourable attitude towards reporting and just over 60% having identified an ADR 
in practice, only 36.9% had ever reported an ADR before. This is a classic case of serious 
under-reporting which is widely publicised in various literature [10, 11, 12]. These results are 
almost similar to a study done at a South African hospital where the vast majority of HCPs 
indicated ADR reporting is necessary (96.2%) and that it is their professional obligation 
(89.4%) but the vast majority had never reported an ADR [13]. 
This study found a significant link between one healthcare profession and the identification 
of ADRs as more medical doctors identified ADRs in practice as compared to nurses 
(p<.001). This is probably due to medical doctors having a wider knowledge base in the field 
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of ADR identification as this is taught more in their academic curricula [9]. Nonetheless, 
there was no significant link in identifying ADRs between pharmacists and medical doctors 
as both HCPs possess almost the same sphere of knowledge in the discipline of ADR 
identification as obtained in their undergraduate training [9]. 
There was no appreciable relationship between the different types of professions and the 
inclination to report ADRs.  As shown by the results of this study, acquiring training on national 
ADR reporting systems remained the benchmark in having a positive impact on both 
identifying and reporting ADRs (p=.003). The TIPC and all other relevant stakeholders need 
to take this into cognizance in their mandate to provide pharmacovigilance training to HCPs. 
Ideally, the TIPC is supposed to have annual pharmacovigilance trainings however this has 
been inconsistent in the last five years due to a lack of funds. One training session was 
conducted in 2017 and another one was co-ordinated in 2019 as well. Health personnel do not 
stay the same, there is always a natural progression of HCPs moving and being replaced by 
those who have not necessarily been trained on ADR reporting before. Interactive methodical 
educational sessions on pharmacovigilance can be utilized in an effort to engage HCPs and 
online training material (including audio-visual material, electronic publications and email 
reminders) can be made available for ease of reference.  Several studies [14, 15] have 
documented how HCPs better understood ADR reporting after the implementation of several 
educational interventions. HCPs in southern India were involved in the pre-KAP (Knowledge, 
Attitude, Practice) questionnaire, an educational intervention, and a post-KAP questionnaire. 
Following the educational intervention, ADR reporting doubled compared to pre-intervention 
[16].   
The Health Professions Council of Namibia (HPCNA) requires every registered HCP to obtain 
a certain number of continuing education units (CEUs) every 12 month period as part of 
continuing professional development (CPD). At least 5 of these CEUs should be for ethics, 
human rights and medical law [17]. In light of the finite knowledge on ADR reporting as a 
whole, it might be prudent to allocate a few requisite CEUs on pharmacovigilance in order to 
better equip HCPs on this issue. This would create a chain in which lives and resources are 
saved from the dis-benefit arising from HCPs who are oblivious to the identification and 
reporting of ADRs. 
The Pharmacy Council of Namibia is involved in the development and ongoing review of the 
academic curriculum for pharmacy students at local universities. The equivalent also applies 
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to the Medical and Dental Council for doctors and the Nursing Council for nurses. In addition 
to HCPs being taught about pharmacovigilance at institution level, equal emphasis should also 
be placed on familiarisation with national guidelines on ADR reporting and not just on 
internationally accepted standards. It is worth pointing out that nurses are likely to see more 
patients and identify more ADRs when doctors are unreachable hence their training on ADR 
reporting should not be trivialized [9]. 
Under-utilization of safety yellow form reporting 
The safety yellow form is wholly used as the reporting tool available at state health facilities 
in the country. The forms are mostly kept at the pharmacy dispensaries as the focal point and 
at some wards and consulting rooms. Less than half of HCPs (48.5%) correctly identified the 
form used to report ADRs in Namibia, furthermore, only 36.9% knew where to obtain the form 
from. These findings are of huge concern. A 2018 study conducted in Turkey also revealed that 
only 34.7% of HCPs knew where to find the ADR reporting form, and 25.5% had previously 
filled the form and/or read it [18].  
The results obtained in this study correlated knowledge of where to obtain the safety yellow 
form with identification (p=.010) and reporting (p<.001) of ADRs. The TIPC, in conjunction 
with hospital management, should make sure that HCPs are aware of the safety yellow form. 
Moreover, supplemental efforts are needed to increase knowledge of where the forms are 
obtained otherwise reporting of ADRs will remain extremely diminished. Department heads 
should ensure continual availability and visibility of forms in their respective wards rather than 
from only one central collection point. Pharmacists, as custodians of medicines, showed 
unparalleled knowledge of the safety form; this is chiefly because the TIPC keeps the majority 
of the forms at the dispensaries. On that account, pharmacists can be used as the focal point to 
inform their professional colleagues about the availability of the safety yellow forms in an 
effort to encourage more ADR reporting. 
Healthcare professionals’ general awareness and knowledge on ADR reporting 
As the drug regulatory unit of the country, the TIPC is relentlessly involved in improving the 
rational and safe use of medicines in Namibia. All ADR reports and pharmacovigilance 
services to both the public and HCPs are solely handled by the TIPC. At best, only 37.9% of 
HCPs knew about the TIPC and were further unfamiliar with the actions that the TIPC can take 
upon receiving reports of suspected ADRs. In line with these actions, a pharmaceutical product 
can be withdrawn from the market; only 65% of HCPs knew this. A change in the labelling of 
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the product to inform healthcare practitioners and consumers of the possible adverse effect is 
also plausible but a reluctant 40.8% of HCPs were aware of this. This is fundamental 
knowledge that all HCPs need to have so that they can swiftly react to circulars from the TIPC 
pertaining to urgent actions that may need to be undertaken. A study on post-marketing 
withdrawal of medicinal products concluded that withdrawal of products following reports of 
suspected adverse reactions, sufficiently serious to affirm withdrawal, has not improved 
consistently over the last few decades and that harmful drugs are less likely to be withdrawn in 
African countries due to lack of knowledge and urgency by HCPs to respond to mandates from 
the regulatory authorities [19]. Moreover, a reduction of ADRs rests on the awareness of HCPs 
to taking heed of subsequent safety-related label revisions [20]. 
Causality assessment of ADRs is a method used for estimating the strength of a relationship 
between drug(s) exposure and the occurrence of ADRs in order to aid signal detection and risk–
benefit decisions regarding medicines [21]. Overall, HCPs had adequate knowledge of 
causality assessment. The only perceptible concern in the study was that 48.5% of HCPs are 
not of the opinion that the pharmacology of a drug can explain the suspected adverse effect but 
it is well known that certain ADRs can be predicted by a drug’s mechanism of action [21]. This 
is significant in helping HCPs to better predict and identify ADRs in real practice. 
ADR severity describes the extent to which the ADRs influence the everyday life of the patients 
[21]. All HCPs unanimously agreed that severe life-threatening ADRs and those causing 
disability should be reported. However, 55.3% do not believe that mild ADRs should be 
reported. A study in Ethiopia also established that a significant proportion of HCPs replied that 
ADRs should be reported only when they are serious and life-threatening and severe and cause 
disability [7]. As much as mild ADRs do not severely affect a patient’s life and might not 
require the complete withdrawal of the drug concerned, they need to be reported too.  
The seriousness of an ADR is related to its life-threatening nature and this can result in far-
reaching consequences such as hospitalization, congenital abnormality and even death of a 
patient. The NMRC guidelines set out that ADR reporting should be done for every 
pharmaceutical product including vaccines, medical devices, blood/biological products and 
herbals/traditional medicines. Just about half of all HCPs (51.5%) indicated that ADRs should 
be reported for herbals and traditional medicines. More knowledge needs to be disseminated 
on the need of taking herbals and traditional medicines into consideration when taking the 
history of a patient whenever an ADR is suspected. In our cultural settings, many people tend 
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to self-medicate at home with well know traditional medicines and herbs and this can have a 
profound impact on other concomitantly administered drugs. Traditional medicines can be 
effective but that is not to say they are completely harmless [22].The safety of many medicinal 
plants used in traditional medicines has been the focus of many studies [22, 23]. 
Conclusion 
This study was conducted in an effort to ascertain if HCPs have awareness and knowledge of 
ADR reporting systems in Namibia. While the results found HCPs knowledgeable on certain 
aspects, it also alluded to the under-reporting of ADRs. The TIPC needs to explore measures 
in order to educate HCPs on pharmacovigilance so that they are better equipped not just to 
identify ADRs, but to report them as well. Awareness of the availability and location of safety 
yellow forms remains equally predominant as this is the reporting tool. Various stakeholders 
in the health sector and government agencies need to come on board in order to unitedly fortify 
pharmacovigilance systems among HCPs in Namibia. 
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CHAPTER 4  
CONCLUSIONS 
 
4.1 Introduction 
This study was carried out to assess awareness and knowledge of HCPs in Namibia regarding 
ADR reporting procedures. The rationale of this study was based on previous research 
conducted in Namibia which highlighted that half of the HCPs in the country were not aware 
of any ADR reporting systems in place, nor had knowledge on how to report ADRs to the TIPC 
[1]. In the case of this study, less than half of all HCPs in the country did not have awareness 
and knowledge of ADR reporting systems in the country. This lack of awareness is not unique 
to Namibia alone, it is also well documented in other countries [2]. In line with one of the many 
recommendations from these precursory studies, this research was done in the public sector to 
ascertain the immensity of this awareness and knowledge among HCPs. 
 
4.1.1 Strengths of the study methodology and design  
The self-administered questionnaires used in the study were easy to follow without any 
supervision from the principal investigator. Furthermore, this study yielded findings with 
minimal costs incurred due to the simplicity of the research tool which was effortlessly 
distributed among the HCPs. In an effort to maintain validity, the questionnaire was first piloted 
to 10 HCPs to remove any possibility of questionnaire irrelevance and of seemingly 
straightforward questions being open to a number of interpretations. The consensus from the 
pilot group was in line with the simplicity and clarity of the research tool. 
Since this study was quantitative and restricted to specific HCPs at the two state hospitals, the 
response rate was good (83.7%).  Data was relatively easy to further analyze so as to deduce 
certain trends and differences among the HCPs in relation to different variables. 
 
4.1.2 Limitations of the study 
• The outcome of this study may not be generalized to other HCPs in the country. 
• More public hospitals will have to be surveyed to enable proper and more diverse 
recommendations for increased ADR reporting awareness and knowledge. 
• Expert sampling could have introduced bias were HCPs felt they needed to respond to 
questions in a certain way in line with the researcher’s expectations.  
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4.2 Conclusions drawn from the study findings 
The aim of this study was to assess awareness and knowledge of doctors, pharmacists and 
nurses in Namibia regarding ADR reporting systems. To achieve this, HCPs were questioned 
to determine the following: 
1. If they understood the term adverse drug reaction and if they had ever encountered it before 
in practice. Knowledge of the terms pharmacovigilance and spontaneous reporting was 
also investigated as well. 
2. If they thought it was necessary to report an ADR and if they deemed it as their professional 
obligation to do so. 
3. Awareness of the TIPC which handles ADR reporting.  
4. Any knowledge of the safety yellow forms for ADR reporting which are available at the 
facilities. 
5. Any training on national ADR reporting systems. 
6. Knowledge of how to identify ADRs in practice and the processes which occur after 
submission of the safety yellow form. 
 
Conclusions drawn from the study findings based on the above research questions 
• Most HCPs (73.8%) could correctly define “adverse drug reaction”; an average number 
(60.2%) had identified an ADR in practice while less than half (41.7%) were subpar in 
correctly defining “spontaneous reporting”. Only 56.3% correctly defined 
“pharmacovigilance”. Comprehension of fundamental terms such as “spontaneous 
reporting” and “pharmacovigilance” among HCPs was not enough and this could adversely 
affect the ability to report ADRs or recognize the importance of reporting ADRs. Pharmacists 
demonstrated a higher level of knowledge of these key terms as the custodians of medicine. 
• A majority (98.1%) of HCPs deemed it necessary as part of their professional obligation to 
report ADRs, but only 36.9% had actually reported an ADR before resulting in profound 
under-reporting. Undetected ADRs due to under-reporting can have far-reaching 
consequences with regards to compromised drug safety. 
• Awareness and knowledge of ADR reporting systems in Namibia among HCPs was low. 
Thirty seven point nine percent of HCPs indicated awareness of the TIPC as the correct drug 
regulatory authority and were oblivious to some of the important actions the TIPC could 
institute following the submission of an ADR report. Forty-eight and a half percent had 
correct knowledge of the safety yellow form for ADR reporting and 63.1% did not know 
where to obtain this form. This lack of knowledge was potentially due to the fact that only 
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36.9% had received training on ADR reporting systems which is highly inadequate. Further 
analysis revealed that training and knowledge of where to obtain the safety yellow form is 
beneficial in identifying and reporting ADRs. 
• The majority of HCPs (84%) were fairly knowledgeable with regards to causality assessment 
to identify ADRs. Satisfactory awareness of ADR severity and seriousness was noteworthy 
although supplemental training will always be needed to complement the knowledge that 
already exists. 
 
4.3 Significance of the study 
• The results of this study give an indication to the extent to which HCPs in Namibia are aware 
of ADR reporting systems in the country with the aim to detect and minimize the occurrence 
of ADRs. ADRs are a major cause of patient-related morbidity and mortality and awareness 
of HCPs to ADR reporting systems in Namibia will play a huge role in effective and safe 
clinical practice [3]. 
• The TIPC as the drug regulatory authority of the country could use the outcome of this study 
to design robust intervention methods and awareness campaigns required to increase or 
improve ADR reporting awareness among HCPs. Accordingly, the TIPC will also be able to 
utilize the outcome of this study to strengthen pharmacovigilance systems as a mandate to 
the Namibian government in ensuring the national provision of medicines which are safe, 
effective and of good quality. 
 
4.4 Recommendations 
• Awareness and training programs designed to improve reporting behavior among HCPs need 
to be implemented by the TIPC in an effort to address the under-reporting of ADRs. 
However, the TIPC alone cannot undertake this engagement. Various stakeholders in the 
health fraternity, including multiple government agencies, need to come on board in a show 
of support to make sure that the TIPC fulfills its ordinance.  
• Pharmacovigilance tutelage needs to be incorporated into the academic curriculum for all 
medical doctors, nurses and pharmacists as the responsibility for ADR reporting is not just 
confined to a single profession. The HPCNA can also aid in the incorporation of mandatory 
pharmacovigilance CEUs as part of the CPD program for all HCPs. 
• The safety yellow form is the reporting tool available in the public health facilities. HCPs 
need to be well informed about how to use this form and where to find it; this can also be 
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done during the orientation of new staff members as well. The availability of the safety 
yellow forms for all hospital departments in clearly marked locations is a requisite. 
• Pharmacists should be utilized as the focal point in pharmacovigilance implementation as 
they displayed better dexterity in the knowledge of ADR reporting systems. The TIPC can 
make use of at least one pharmacist already based in that particular facility as a 
pharmacovigilance officer. 
• The TIPC needs to routinely update its website and encourage the use of the online ADR 
form submission function in order to enhance electronic reporting. 
 
4.5 Chapter summary 
This final chapter highlighted the conclusions drawn from the findings of the study, described 
the significance, strengths and limitations of the study, as well as provided recommendations 
for improving awareness and knowledge among HCPs to ADR reporting systems in the 
country. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 
 
 
REFERENCES 
 
1. Adenuga, B.A., Kibuule D. (2018). A case for strengthening pharmacovigilance systems 
in Namibia. (http://gjmedph.com/uploads/VP1-Vo7No1.pdf) Accessed 12/01/2020 
2. Generali, J. A. (2014). Adverse drug event reporting: awareness is not enough. Hospital 
Pharmacy, 49(2), 110. 
3. Adverse drug events costly to healthcare system: Vancouver Coastal Health-UBC 
research. (2016) (https://news.ubc.ca/2011/02/25/adverse-drug-events-costly-to-health-
care-system-vancouver-coastal-health-ubc-research/) Accessed 9/12/2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
39 
 
ANNEXURE 1 
Ethical approval obtained from the University of KwaZulu-Natal 
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ANNEXURE 3 
Safety yellow form used in Namibia 
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ANNEXURE 4 
Research Questionnaire 
 
Questionnaire 
 
1)     Profession 
  □ Medical Doctor □ Pharmacist □Nurse 
 
2) Gender                                             
 □ Male                     □ Female 
 
3)     Educational qualifications attained? 
 □ Diploma 
 □ Postgraduate Diploma 
 □ Degree 
 □ Masters Degree 
 □ PhD 
 
4)     Number of years in practice? 
 □ Less than a year 
 □ 1-5 years 
 □ 6-10 years 
 □ 11-20 years 
 □ More than 20 years  
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5) What do you understand under by the term “Adverse Drug 
Reaction?” 
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
________________________________________ 
 
6) What do you understand by the term “Pharmacovigilance?”  
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
_________________________ 
 
7)    What do you understand from “Spontaneous reporting” of adverse 
effects of medicine?  
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
_________________________ 
 
          8)  Which of the following do you need to know when you need to    
decide if an effect was caused by a medicine? (Choose all appropriate 
options)  
□ Know all the medication the patient is currently taking. 
□ Know the timing between administration of the medicine and 
development of the suspected adverse effect.  
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□ Know if re-exposure worsens the suspected adverse effect OR 
withdrawal of medicine decreases the suspected adverse effect?   
□ Know that the pharmacology explains the suspected adverse effect?  
 
9)    ADRs should be reported for which of the following products? 
(Choose all appropriate options)  
□ Herbals and traditional medicines.  
□ Vaccines and medical devices. 
□ Biological and blood products. 
□ Only prescribed medicines with a low therapeutic index.    
     
10)    Which types of ADRs should be reported? (Choose all appropriate 
options)  
□ Severe and life threatening. 
□ Severe and causing disability. 
□ Mild and cause less. 
 
11)    Do you believe clinical trials during medicine development are 
sufficient to identify ALL adverse effects a medicine might have?  
□ YES   □ NO  
 
12)    Which of the following might be the result of an adverse effect 
caused by a medicine? (Choose all appropriate options)  
 □ Hospitalization.   
 □ Life threatening situation. 
 □ Congenital abnormality. 
 □ Death of a patient. 
 
46 
 
        13)   Have you ever identified an adverse reaction in practice?  
         □ YES   □ NO 
 
14)   Have you ever reported an adverse drug reaction?      
 □ YES   □ NO        
If you answered YES, WHO did you report the adverse drug reaction 
to? 
…………………………………………………………………………………………………………. 
 
15) Do you believe it is necessary to report an ADR?                                           
□ YES □ NO     
 
16)    Have you ever been trained on how to report an ADR?  
□ YES  □ NO 
 
17)    Have you ever, formally or informally, been informed about 
systems for ADR reporting in Namibia?                
 □ YES □ NO 
 
18) What is the report form used to report adverse drug reactions in 
Namibia?                                                     
□ Medwatch form. 
□ Sentinel event reporting form. 
□ Safety yellow form. 
 
19)    Do you know where to obtain the form in (18)?   
□ YES   □ NO  
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20)  Who must you submit this form to?  
 □ Monitoring centre for therapeutics Namibia.  
 □ Namibia pharmacovigilance monitoring centre. 
 □ Therapeutics information and pharmacovigilance centre. 
 
21)    Which of the following can the regulatory authority do based on 
reports of adverse drug reactions reported to them? (Choose all 
appropriate options)  
□ Withdraw the product from the market. 
□ Change on the labelling of the product to inform healthcare 
practitioners / consumers of the possible adverse effect. 
□ Send out alerts to prescribers and consumers to inform them of a 
possible adverse reaction. 
□ Keep the suspect drug in the market despite the adverse effects for 
as long as possible provided its patent is still active.    
 
22).  Who is responsible for ADR Reporting?  (Choose all appropriate 
options) 
□ Doctors □ Pharmacists □ Nurses 
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ANNEXURE 5 
Information sheet and consent to participate in research study 
 
Date: 01/10/2019 
 
Dear Healthcare Professional 
 
My name is Garnet Ndlovu and I am a postgraduate student in the College of Health 
Sciences at the University of Kwazulu-Natal in South Africa. 
 
You are being invited to participate in a study investigating knowledge of healthcare 
professionals about adverse drug reaction reporting systems in Namibia. The study will 
expect you to complete a questionnaire with questions related to adverse reactions and the 
reporting of these in Namibia. We hope that the study will provide insight into how to 
improve and strengthen pharmacovigilance systems which are needed to ensure drug safety.   
  
This study does not involve any risks.  
 
This study has been ethically reviewed and approved by the UKZN Biomedical research Ethics 
Committee (approval number BE 489/19). 
 
In the event of any problems or concerns/questions you may contact me on 0817550358 or 
by email garnetndlovu@yahoo.co.uk or the UKZN Biomedical Research Ethics Committee, 
contact details as follows:  
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za  
 
Participation in this research is voluntary and participants may withdraw participation at 
any point, and that in the event of refusal/withdrawal of participation the participants will 
not incur penalty.  
 
All the information collected will remain confidential without any possibility of being traced 
back to the participant. 
 
 
---------------------------------------------------------------------------------------------------------------
--- 
 
 
 
 
 
 
49 
 
 
 
 
 
 
CONSENT  
 
I………………………………………..have been informed about the study entitled ‘Awareness and 
knowledge of doctors, pharmacists and nurses on ADR reporting systems in Namibia - a study 
at two state hospitals in the Khomas and Hardap regions’ by the researcher Garnet Ndlovu. 
 
I understand the purpose and procedures of the study. 
 
I have been given an opportunity to answer questions about the study and have had answers 
to my satisfaction. 
 
I declare that my participation in this study is entirely voluntary and that I may withdraw at 
any time without affecting any care that I would usually be entitled to. 
  
If I have any further questions/concerns or queries related to the study I understand that I 
may contact the researcher on 0817550358 or by email at garnetndlovu@yahoo.co.uk 
 
If I have any questions or concerns about my rights as a study participant, or if I am 
concerned about an aspect of the study or the researchers then I may contact: 
  
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za  
 
 
 
____________________      ____________________ 
Signature of Participant                            Date 
 
 
____________________   _____________________ 
Signature of Witness                                Date 
(Where applicable)      
 
 
____________________   _____________________ 
Signature of Translator                            Date 
(Where applicable) 
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ANNEXURE 6 
Author guidelines for manuscript publication: Journal of pharmacy practice 
Pharmacy Practice supports and is supported by the fundamentals of scholarly publishing. 
Authors considering submit a paper to Pharmacy Practice must follow a strict code of 
conduct based on the Recommendations for the Conduct, Reporting, Editing, and 
Publication of Scholarly work in Medical Journals, especially on regards Roles & 
Responsibilities and the Scientific Misconduct of the authors and collaborators. 
 Originality of the text in manuscripts is checked by the text-similarity detection 
service Crossref Similarity Check. 
 Correspondence author is responsible of including all the authors that granted the 
right to be author, but also to not include any individual who does not deserve the 
authorship. Notwithstanding, Pharmacy Practice has no limit in the number of 
authors per paper, we recommend double checking the criteria to consider a 
contributor as an author, and also to consider if the role of Collaborator or a simple 
acknowledgement are more appropriate. 
 If a scientific misconduct is suspected, COPE flowcharts will be applied with no 
restriction, as we did in the past (Pharm Pract (Granada) 2012;10(1):1-2). 
Authors are encouraged to visit the Instructions for Reviewers to see how these crucial 
collaborators should evaluate the manuscript. 
Additional recommendations, applicable to any category of articles: 
 Abstract should have no more than 350 words and no less than 250 (in Original 
research articles, abstracts should be structured in Background, Objective, 
Methods, Results, and Conclusion). 
 Only Keywords based on NLM Medical Subject Headings are used. 
 References should be cited in the main text as numbers in superscript at the end of 
sentences (always after the period). The list of references should be numbered and 
ordered as they were cited in the text. 
 Reference format should follow ICMJE recommendations (Citing Medicine) and 
journal titles must be abbreviated according to the MEDLINE style, available at 
the NLM Catalog. 
 Tables must appear at the end of the text, formatted as follows: 
o  
 Use simple grid without merging cells. No cells shading is allowed. 
 Font must be Calibri 8pt; line spacing: simple. 
 Orientation of the page containing the table must be: portrait. 
 Table should fit into one page. Oversized tables will be moved to 
online appendix. 
 Figures are preferred pasted as Microsoft Objects. Color use should take into 
account that papers can be printed in black and white. 
 Avoid the abuse of abbreviations. Use only abbreviations commonly accepted. Do 
not create new abbreviations. 
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 Avoid the use of non-common Roman characters. Do not use Greek letters into the 
text (they can be used in equations). Do not use special characters like ± ½ ¼ or 
arrows. 
 Present standard deviations as (SD=2.34), and confidence intervals as [95%CI 
2.36:4.23] 
 For currency abbreviations, use the ISO 4217 codes. 
 Follow International standards for author’s names and abbreviations. John Philip 
Doe will be abbreviated as Doe JP. Download here an Excel file to see how your 
name will be abbreviated following International standards. 
 [NEW RULE for 2020] Provide only one institution for each author’s affiliation. 
Affiliations must be translated into English (no exceptions to this rule). Candidate 
positions are not considered. 
 For non-native English authors, a scientific editing service could be required. See 
below a list of some of these scientific editing providers. Authors using this service 
should include a sentence in the acknowledge section. 
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ANNEXURE 7 
Journal submission letter 
 
